Identification of Signal of Clindamycin Associated Renal Failure Acute: A Disproportionality Analysis

Abstract

Background: Early signal detection from post-marketing studies play a vital role in the safety of patients. Recent case reports have indicated the association of clindamycin with renal failure acute. However, renal failure acute is not known to be associated with clindamycin. The aim of the study was the identification of the potential signal of clindamycin-associated renal failure acute. background: Early signal detection from post-marketing studies play a vital role in the safety of patients. Recent case reports have indicated the association of clindamycin with acute renal failure. However, acute renal failure is not known to be associated with clindamycin. Methods: The OpenVigil 2.1-MedDRA-v24 was used to query the FAERS database. The Reporting Odds Ratio (ROR) with a 95% confidence interval, was used to assess the association between clindamycin and renal failure acute. Results: A total of 22326 cases associated with renal failure acute were found in OpenVigil 2.1-MedDRA-v24. Among these 125 were associated with clindamycin. The ROR was found to be 3.2 (2.7, 3.8) which indicates a statistically significant association between clindamycin and renal failure acute reporting. The signal strength was decreased after removing the cases of concomitantly administered drugs, however, the association of clindamycin with renal failure acute reporting remains statistically significant. The subgroup analysis results have also shown a positive signal of clindamycin with renal failure acute. method: The OpenVigil 2.1-MedDRA-v24 was used to query the FAERS database. The Reporting Odds Ratio (ROR) with 95% confidence interval, was used to assess the association between clindamycin and acute renal failure Conclusions: The current study identified a positive signal of clindamycin as acute renal failure. However, further validation and causality assessment are required. result: A total of 22326 cases associated with acute renal failure were found in OpenVigil 2.1-MedDRA-v24. Among which 125 were associated with clindamycin. The ROR was found to be 3.2 (2.7, 3.8) which indicates a statistically significant association between clindamycin and acute renal failure reporting. The signal strength was decreased after removing the cases of concomitantly administered drugs, however, the association of clindamycin with acute renal failure reporting remains statistically significant. The subgroup analysis results have also shown a positive signal of clindamycin with acute renal failure. conclusion: The current study identified a positive signal of clindamycin as acute renal failure. However, further validation and causality assessment are required. other: None

Drugs associated with a risk of supraventricular tachycardia: analysis using the OpenVigil database

“…These objectives can be achieved by analyzing adverse drug reactions using the OpenVigil database. 18,19 A total of 126 drugs, including sex hormones, antidiabetics, peptidase inhibitors, antivirals, nicotinic acetylcholine receptor agonists, and tyrosine kinase inhibitors, have previously been identified in a search of the OpenVigil database for reverse signals to find drugs targeting viral respiratory infections or diseases caused by RNA viruses. 20 In the present research, we used the OpenVigil database to analyze the risk of drug-related SVT and to categorize, organize, and summarize those drugs that might cause SVT.…”

Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database

“…The US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) is a spontaneous reporting system (SRS) used to assess potential associations between drugs and AEs ( Sharma and Kumar, 2022 ; Shu et al, 2022 ). Disproportionality analysis is a common method used to detect signals in drug vigilance databases and is employed to identify unknown AEs ( Noguchi et al, 2021 ; Javed and Kumar, 2024 ). The reporting odds ratio (ROR) is a method of frequency disproportionality analysis, while the information component (IC) is a component of Bayesian disproportionality analysis ( Ji et al, 2021 ).…”

Endocrine system-related adverse events associated with PD-1/PD-L1 inhibitors: data mining from the FDA adverse event reporting system

“…The disproportional reporting is most usually employed in adverse drug events signal monitoring, which containing reporting odds ratio (ROR), comprehensive standard (MHRA) and proportional reporting ratio (PRR) methods. Up to date, there are numerous studies have been applied these methods in drug safety investigation (11)(12)(13).…”